James Thorburn - Twist Bioscience Chief Officer
| TWST Stock | USD 40.81 0.39 0.95% |
Executive
Mr. James M. Thorburn has served as our Chief Financial Officer since April 2018. Prior to joining us, Mr. Thorburn served as a member of the board of directors of IXYS Corporation, a publicly traded semiconductor company from March 2007 to January 2018. Mr. Thorburn was also Chief Sales Officer and CoHead of International at Televerde, a demand generation and sales acceleration enterprise, from August 2014 to February 2018. Prior to Televerde, he served as interim CFO of several public and private companies including Enercore, Next Autoworks, Fisker Automotive and Numonyx. Mr. Thorburn served as Chief Executive Officer of Zilog from March 2001 until August 2006. Prior to serving as Chief Executive Officer of Zilog, Mr. Thorburn held various executive positions including Chief Operating Officer of ON Semiconductor, operating consultant with Texas Pacific Group, Chief Financial Officer at Zilog and various management positions at National Semiconductor Corporation since 2018.
| Age | 68 |
| Tenure | 7 years |
| Address | 681 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 800 719 0671 |
| Web | https://www.twistbioscience.com |
Twist Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.1524) % which means that it has lost $0.1524 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3773) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.38 in 2025. Return On Capital Employed is likely to drop to -0.38 in 2025. Non Current Liabilities Total is likely to gain to about 86.5 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 49 M in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sallilyn Schwartz | Illumina | N/A | |
| MD MBA | Natera Inc | N/A | |
| Mary Finnegan | Mettler Toledo International | N/A | |
| Christos Ross | Waters | N/A | |
| Michael Esq | Thermo Fisher Scientific | 63 | |
| Jing Huang | Caredx Inc | N/A | |
| Daniel LLM | Natera Inc | 56 | |
| Gerhard Keller | Mettler Toledo International | 57 | |
| Michelle Roe | Mettler Toledo International | 54 | |
| Gregg Dearhammer | IQVIA Holdings | N/A | |
| Kathryne Reeves | Illumina | 55 | |
| Robert Schueren | Natera Inc | 62 | |
| Deepshikha Bhandari | Personalis | N/A | |
| Peter Schueler | ICON PLC | N/A | |
| Pat Leckman | Illumina | 60 | |
| Jerry Diffley | Natera Inc | N/A | |
| Kashif Rathore | Caredx Inc | N/A | |
| Nicholas Childs | IQVIA Holdings | N/A | |
| Robert Woodward | Caredx Inc | N/A | |
| Jeffrey CFA | EXACT Sciences | 46 | |
| Jakob Wedel | Illumina | N/A | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.15 |
Twist Bioscience Corp Leadership Team
Elected by the shareholders, the Twist Bioscience's board of directors comprises two types of representatives: Twist Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Twist. The board's role is to monitor Twist Bioscience's management team and ensure that shareholders' interests are well served. Twist Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Twist Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emily Leproust, President CEO, Director | ||
| William Banyai, GM Development | ||
| Patrick Finn, Vice President of Sales and Marketing | ||
| Dennis JD, Chief VP | ||
| Kevin Yankton, VP Officer | ||
| Chet Gandhi, Chief Officer | ||
| Michael Fero, Chief Officer | ||
| Nicole Moreno, Senior Support | ||
| Siyuan Chen, Chief Officer | ||
| Aaron Sato, Chief Officer | ||
| Dennis Cho, General VP | ||
| James Thorburn, Chief Officer | ||
| Erin Smith, Sr Policy | ||
| Adam Laponis, Chief Officer | ||
| Paula Green, Vice President of Human Resources | ||
| Angela Bitting, Chief Affairs | ||
| Robert Werner, VP Officer |
Twist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Twist Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (0.60) % | ||||
| Operating Margin | (0.39) % | ||||
| Current Valuation | 2.26 B | ||||
| Shares Outstanding | 59.65 M | ||||
| Shares Owned By Insiders | 2.24 % | ||||
| Shares Owned By Institutions | 97.76 % | ||||
| Number Of Shares Shorted | 8.64 M | ||||
| Price To Book | 5.38 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.